NCT04682652 (GRAVITY) is a NA clinical trial of Embozene MicroSpheres in Knee Osteoarthritis, sponsored by University of California, Los Angeles.

Who is sponsoring NCT04682652?

NCT04682652 is sponsored by University of California, Los Angeles.

What drugs are being tested in NCT04682652?

Interventions in NCT04682652: Embozene MicroSpheres.

What condition does NCT04682652 study?

NCT04682652 studies Knee Osteoarthritis, Degenerative Joint Disease of Knee.

Is NCT04682652 still recruiting?

NCT04682652 is currently recruiting now. Last updated 3 October 2025.

Last reviewed 2025-10-03 · How we verify

NCT04682652: GRAVITY

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Genicular Artery Embolization Vs Observation for Symptomatic Knee Osteoarthritis

Recruiting now NA Last updated 3 October 2025

What this trial tests

NA trial testing Embozene MicroSpheres in Knee Osteoarthritis in 100 participants. Currently enrolling.

Timeline

1 August 2023

Primary endpoint
1 October 2026

1 October 2027

Quick facts

Lead sponsor	University of California, Los Angeles
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	none
Primary purpose	treatment
Enrollment	100
Start date	1 August 2023
Primary completion	1 October 2026
Estimated completion	1 October 2027
Sites	1 location across United States

Drugs / interventions tested

Embozene MicroSpheres — full drug profile →

Conditions studied

Knee Osteoarthritis — all drugs for Knee Osteoarthritis →
Degenerative Joint Disease of Knee — all drugs for Degenerative Joint Disease of Knee →

Sponsor

University of California, Los Angeles

Who can join

Adults 40 to 79, any sex, with Knee Osteoarthritis or Degenerative Joint Disease of Knee. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this clinical trial is to determine whether genicular artery embolization (GAE) is an effective way to treat knee pain from osteoarthritis. Pain from arthritis is often due to underlying inflammation in the joint. The inflammation is associated with increased abnormal blood flow going to the specific area of pain. If the investigator can reduce the blood flow, the inflammation can be reduced and the pain can be controlled. The GAE procedure is an experimental procedure to decrease the blood flow (embolize) to the specific region of the knee that is causing the pain. This will be done by infusing microscopic spheres into the specific blood vessel (genicular artery) supplying the area of pain in the knee. This is done through a procedure which is called an angiogram, which is done entirely through a pinhole at the creased of the thigh, using twilight (conscious) sedation. The investigators have already completed an initial trial at UCLA, and shown that this procedure is safe and effective. The purpose of this new trial is to compare outcomes of people undergoing the GAE procedure to those who do not undergo the procedure. A total of 100 patients will be enrolled, and 2/3 of the patients will be randomly selected to undergo the GAE procedure. 1/3 will not undergo the procedure. This is known as a randomized trial. During the trial, all subjects will also get MRIs and fluid withdrawn from their knee joints at various timepoints in order to precisely figure out how the procedure works on a closer (microscopic) level.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Embozene MicroSpheres

Trials testing the same drug.

NCT03491397 — Genicular Artery Embolization for the Treatment of Knee Osteoarthritis · NA · completed

Other recruiting trials for Knee Osteoarthritis

Currently open trials in the same condition.

NCT06906939 — A Randomized Pilot rTMS Trial for Knee Arthritis Pain and Depression · EARLY_PHASE1 · recruiting
NCT05823727 — Effects of Collagen Peptide Supplementation on Connective Tissue Remodeling, Functional Outcomes, and Wound Healing Afte · NA · recruiting
NCT07370480 — Knee Osteoarthritis and Thermal Spa Treatment · NA · recruiting
NCT07507175 — Gastrocnemius Myofascial Release in Females With Knee Osteoarthritis · NA · recruiting
NCT07386600 — Dexamethasone vs Dexmedetomidine for iPACK + ACB in TKA · NA · recruiting

Other University of California, Los Angeles trials

Trials by the same sponsor.

NCT04846517 — rTMS for Aneroxia Nervosa in Youth · NA · not yet recruiting
NCT06701760 — Sodium Lactate in Severe TBI · Phase 2 · not yet recruiting
NCT04996667 — Effect of iNO in Patients With Submassive and Massive PE · Phase 2 · withdrawn
NCT05067387 — Evaluation of Oral THC and CBD in Men and Women · Phase 1 · not yet recruiting
NCT07534696 — Evaluation of Non-Invasive Pelvic Floor Neuromuscular Stimulation for Urinary Incontinence After Prostatectomy · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04682652 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of California, Los Angeles
Last refreshed: 3 October 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04682652.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing